Your browser doesn't support javascript.
Chloroquine in fighting COVID-19: good, bad, or both?
Tang, Daolin; Li, Jingbo; Zhang, Ruoxi; Kang, Rui; Klionsky, Daniel J.
  • Tang D; The Third Affiliated Hospital, Guangzhou Medical University , Guangzhou, Guangdong, China.
  • Li J; Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.
  • Zhang R; Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.
  • Kang R; Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.
  • Klionsky DJ; Department of Surgery, UT Southwestern Medical Center , Dallas, TX, USA.
Autophagy ; 16(12): 2273-2275, 2020 12.
Article in English | MEDLINE | ID: covidwho-671715
ABSTRACT
Coronavirus disease 2019 (COVID-19) has attracted worldwide attention due to its speed of progression and elevated mortality rate. Amid the rush to develop treatments, recent hopes have focused on the anti-malarial drug chloroquine or the derivative hydroxychloroquine. Here, we briefly discuss the evidence for the potential use of these drugs with regard to the current pandemic.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chloroquine / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia / Europa Language: English Journal: Autophagy Year: 2020 Document Type: Article Affiliation country: 15548627.2020.1796014

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chloroquine / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia / Europa Language: English Journal: Autophagy Year: 2020 Document Type: Article Affiliation country: 15548627.2020.1796014